Boston Scientific launches global restructuring plan with $700 million-$800 million in charges

• Boston Scientific launched a global restructuring plan on July 21, 2026 to drive cost efficiencies and support strategic priorities.
• Program runs from 2026 through 2029, centered on supply chain optimization, production line transfers, functional transformation.
• Total pre-tax charges estimated at $700 million-$800 million, including $600 million-$700 million in expected future cash outlays.
• Targeted to cut gross annual pre-tax expenses by about $500 million as benefits phase in.
• Headcount reductions expected, with savings largely earmarked for reinvestment in growth initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000885725-26-000049), on July 27, 2026, and is solely responsible for the information contained therein.